Castle Biosciences CEO Executes Pre-Arranged Sales Under Rule 10b5-1 Plan
Castle Biosciences Inc. (NASDAQ:CSTL) President and CEO Derek J. Maetzold executed a series of stock transactions on July 1, 2026, resulting in the sale of 9,834 shares for approximately $238,916. The sales, conducted via a Rule 10b5-1 trading plan adopted in December 2025, involved both direct holdings and shares held in various family trusts. Con…